DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Key Inclusion Criteria:

• Adults ≥ 18 years of age who are willing and able to provide written informed consent
• Have an ECOG performance status of ≤ 1. Subjects with an ECOG performance status of 2may be enrolled with Medical Monitor approval.
• Pathologically confirmed diagnosis of DLBCL, as defined by the 2016 World HealthOrganization classification including DLBCL NOS high-grade B-cell lymphoma with MYCand BCL2 and/or BCL6 rearrangements, Epstein-barr virus (EBV) positive DLBCL, and Tcell rich B cell lymphoma (TCRBCL). Subjects with DLBCL transformed from indolentlymphoma (except for Richter's transformation) are eligible.
• Subjects must have progressive disease following at least two (2) lines of priorsystemic therapy for DLBCL; prior treatment must have included an anthracycline andrituximab (or another CD20-targeted agent).
• Subjects must have failed or be ineligible for ASCT or CAR-T
• Have at least one bi-dimensionally measurable lesion per Lugano (2014)
• Willing to provide pre-treatment and on-treatment tumor biopsy tissue.
• Meet protocol-specified laboratory requirements
• Life expectancy > 3 months.

Key Exclusion Criteria:

• Primary CNS lymphoma or active secondary CNS involvement and/or lymphomatousmeningitis
• Chemotherapy, immunotherapy, major surgery, or investigational agent treatment within 28 days of D0 or 5 half-lives, whichever is shorter
• Radiotherapy within 14 days of day 0
• Autologous stem cell transplant (ASCT) within ˂100 days prior to D0
• Chimeric antigen receptor T cell (CAR-T) therapy within ˂28 days prior to D0
• Diagnosis of immunodeficiency disorder or history of active autoimmune disease thathas required systemic treatment in the past 2 years
• Uncontrolled significant active infections (controlled Hepatitis B, Hepatitis C, orHIV may be eligible)
• Prior history of malignancy other than eligible lymphoma sub-types, unless the subjecthas been free of the disease for ≥ 2 years prior to the start of study treatment